GSK has been at the forefront of the genomics revolution because of its potential to maximize the chances of successful new medicines. Over the last few years, we’ve invested in multiple collaborations in genetics and genomics, and we’ve built an in-house AI/ML team. The result has been an explosion of data and a seemingly infinite number of possible discovery pathways. Last year, GSK produced more data in one quarter than in our entire 300-year history. We’ve made huge strides, so our ambition now is to supercharge our data capabilities in order to accelerate the pace of discovery and increase the impact our scientists can make to help patients.
To create this ecosystem, our goal is to connect and add context to all our structured and unstructured data. Through adding semantic metadata to the data generated by our in-house departments and external sources and collaborators, we give context to the diseases, genes, proteins and assets we study, removing any ambiguity and ensuring consistency. The improvement in data connectivity will result in accessibility increasing dramatically, taking our scientists mere minutes to find the right data and empowering them to predict more about human health and develop better medicines for the future in faster and more effective ways.
Semantically enriched data also facilitates the construction of knowledge graphs, which provide our scientists with connected data and enable natural language questioning, which again will transform the day-to-day life of our scientists.
We’re investing in and building bespoke tools, hiring world-class data engineers and technologists in London, San Francisco, Seattle and Boston, and we are instilling a digital first mindset to fuel our entire R&D enterprise to “free up minds and hands”.
If this sounds exciting to you and you want to put your skills towards improving the health of billions, have a look at our current job opportunities.
